Oncoinvent ASA (OSL:ONCIN)
90.60
-0.60 (-0.66%)
Aug 27, 2026, 10:58 AM CET
Oncoinvent ASA Revenue
Oncoinvent ASA had revenue of 8.20M NOK in the half year ending June 30, 2026, with 12,143.28% growth. This brings the company's revenue in the last twelve months to 24.31M, up 3,470.04% year-over-year. In the year 2025, Oncoinvent ASA had annual revenue of 28.07M with 246.40% growth.
Revenue (ttm)
24.31M
Revenue Growth
+3,470.04%
P/S Ratio
14.55
Revenue / Employee
637.93K
Employees
44
Market Cap
408.43M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 28.07M | 19.97M | 246.40% |
| Dec 31, 2024 | 8.10M | 7.75M | 2,188.98% |
| Dec 31, 2023 | 354.00K | -5.93M | -94.37% |
| Dec 31, 2022 | 6.28M | 5.51M | 711.76% |
| Dec 31, 2021 | 774.00K | 173.00K | 28.79% |
| Dec 31, 2020 | 601.00K | -8.30M | -93.25% |
| Dec 31, 2019 | 8.90M | 6.57M | 281.16% |
| Dec 31, 2018 | 2.34M | - | - |
| Dec 31, 2017 | 0 | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ArcticZymes Technologies ASA | 133.41M |
| Arctic Bioscience AS | 42.62M |
| SoftOx Solutions AS | 16.27M |
| Aqua Bio Technology ASA | 7.53M |
| Nykode Therapeutics AS | 4.60M |
| Thor Medical ASA | 839.00K |
| Lytix Biopharma ASA | 377.00K |
| Circio Holding ASA | 123.00K |
Oncoinvent ASA News
- 1 hour ago - Oncoinvent ASA Quarterly report: H1 2026 - Filings
- 1 hour ago - Oncoinvent ASA Slides: H1 2026 - Filings
- 6 days ago - Oncoinvent ASA Slides: Investor presentation - Filings
- 3 months ago - Oncoinvent ASA Slides: Investor presentation - Filings
- 4 months ago - Oncoinvent ASA Transcript: Investor update - Transcripts
- 4 months ago - Oncoinvent ASA Slides: Investor update - Filings
- 6 months ago - Oncoinvent ASA Slides: DNB Carnegie Nordic Healthcare Conference presentation - Filings
- 6 months ago - Oncoinvent ASA Earnings Call Transcript: Q4 2025 - Transcripts